Presymptomatic compensation in Parkinson's disease is not dopamine-mediated (Q35104797)

6 August 2017

1 reference

title

Presymptomatic compensation in Parkinson's disease is not dopamine-mediated (English)

1 reference

6 August 2017

1 reference

3

Jonathan M Brotchie

1 reference

6 August 2017

Erwan Bezard

1

1 reference

PubMed ID

12689773

6 August 2017

Christian E Gross

series ordinal

2

1 reference

6 August 2017

1 April 2003

1 reference

6 August 2017

Trends in Neurosciences

1 reference

6 August 2017

26

1 reference

6 August 2017

4

1 reference

6 August 2017

215-221

1 reference

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Clinical observations on the rate of progression of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Compensations after lesions of central dopaminergic neurons: some clinical and basic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Presymptomatic revelation of experimental parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

The relationship between MI and SMA afferents and cerebellar and pallidal efferents in the macaque monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Parkinson's disease: imaging update.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Functional imaging of Parkinson's disease: is it possible to detect brain areas for specific symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

Parkinson's disease: pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2803%2900038-9

7 January 2021

10.1016/S0166-2236(03)00038-9

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12689773